Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection-Reference-Cited by-同舟云学术

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

Published:2018-09 Issue: Volume:129 Page:27-39
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Banna Giuseppe Luigi^ORCID,Passiglia Francesco,Colonese Francesca,Canova Stefania^ORCID,Menis Jessica,Addeo Alfredo,Russo Antonio,Cortinovis Diego Luigi^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference139 articles.

1. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection;Ahmed;Am. J. Gastroenterol.,1999

2. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discovery,2013

3. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

4. Durvalumab after chemoradiotherapy in stage III Non-small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

5. Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC;Arbour;J. Clin. Oncol.,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targets for immune-checkpoint inhibition in cancer;Cancer Treatment Reviews;2023-11

2. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer;Lung Cancer;2023-10

3. Assessing the role of colonic and other anatomical sites uptake by [¹⁸F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors;Thoracic Cancer;2023-07-13

4. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors;Critical Reviews in Oncology/Hematology;2022-11

5. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study;International Immunopharmacology;2022-09